• Korean Journal of Radiology
• /
• 제19권6호
• /
• pp.1196-1197
• /
• 2018

• 대한핵의학회지
• /
• 제38권2호
• /
• pp.152-160
• /
• 2004

Radioiodide uptake in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy. NIS gene transfer to tumor cells may significantly and specifically enhance internal radioactive accumulation of tumors following radioiodide administration, and result in better tumor control. NIS gene transfers have been successfully performed in a variety of tumor animal models by either plasmid-mediated transfection or virus (adenovirus or retrovirus)-mediated gene delivery. These animal models include nude mice xenografted with human melanoma, glioma, breast cancer or prostate cancer, rats with subcutaneous thyroid tumor implantation, as well as the rat intracranial glioma model. In these animal models, non-invasive imaging of in vivo tumors by gamma camera scintigraphy after radioiodide or technetium injection has been performed successfully, suggesting that the NIS can serve as an imaging reporter gene for gene therapy trials. In addition, the tumor killing effects of I-131, ReO4-188 and At-211 after NIS gene transfer have been demonstrated in in vitro clonogenic assays and in vivo radioiodide therapy studies, suggesting that NIS gene can also serve as a therapeutic agent when combined with radioiodide injection. Better NIS-mediated imaging and tumor treatment by radioiodide requires a more efficient and specific system of gene delivery with better retention of radioiodide in tumor. Results thus far are, however, promising, and suggest that NIS gene transfer followed by radioiodide treatment will allow non-invasive in vivo imaging to assess the outcome of gene therapy and provide a therapeutic strategy for a variety of human diseases.

• 대한두경부종양학회지
• /
• 제8권1호
• /
• pp.14-20
• /
• 1992

To clarify the safety of both total and near-total thyroidectomy, and to guide a selectionof an adequate type of surgical treatment of thyroid diseases, 192 consecutive total or near-total thyroidectomy cases were reviewed. They were divided into two groups: ont, the total thyroidectomy group(Group T,N=111) and the other, the near-total thyroidectomy group (Group NT, N=81). In both groups, complication rates, associations of complication rates with extents of surgery and stage of lesion were observed. Complication rate was significantly higher in Group T (53.6% vs 12.3%, p<0.05). But the rate of permanent complications such as permanent hypoparathyroidism and recurrent laryngeal nerve injury was remarkably low(4.5% in Group T, 6.0% in Group NT) and shows no significant difference in both groups. There was no permanent complication in cases where any type of neck dissection had not been performed regardless of the type thyroidectomy. But among whom underwent central compartmental neck dissection(CCND) and functional neck dissection(FND), 4(4.4%) and 4(6.4%) cases showed permanent complications. There was no statistical significance in differences between Group I and NT. In cases who underwent concomittant classical radical neck dissection(RND), 3(25.5%) showed permament complications. In this subgroups, complications were significantly higher in Group T(p<0.005). Complications were also directly related to the stage of the lesion. Only one patient showed permanent complication in 74 intracapsular lesions but 9 permanent complications were observed in 118 advanced lesions. We could clarify both total and near-total thyroidectomy were safe operations and the complications were related to accompanying neck dissections and the disease status rather than total or near-total thyroidectomy itself. Thus, we think that for the cases where higher complication rates are expected, such as locally advanced thryoid cancers or the cases which required wider neck dissection, the near-total thyroidectomy would be a preferrable method.

• 대한핵의학회지
• /
• 제31권3호
• /
• pp.372-380
• /
• 1997

암으로 수술을 받은 104명의 환자를 대상으로 수술 후 암의 재발 판정을 위하여 FDG PET를 시행하였다. 대상환자는 뇌종양 14명, 두경부 암 15명, 부인과 암 23명, 소화기계 암 16명, 갑상선 암 16명, 기타 암 20명이었다. 기존의 방사선학적 검사법인 CT, MRI 등을 함께 시행하였고 종양표지자를 측정하여 PET소견과 비교하였다. 재발유무를 조직검사나 임상 경과 관찰에 의하여 판정하였다. FDG PET는 암의 재발 판정에 있어서 94%의 예민도와 92%의 특이도를 보여주었다. CT나 MRI 등 기존의 방사선학적 진단법의 예민도는 78%, 특이도는 68% 이었으며 대장암, 난소암, 갑상선암에서 측정된 종양표지자는 예민도 71%, 특이도 84%를 보였다. 난소암 등 부인과암과 뇌종양에서 특히 PET는 다른 진단법에서보다 높은 진단 능력을 보여 주었다. 전신 FDG PET는 암의 재발 판정을 위해 유용하게 이용될 수 있을 것으로 생각한다.